Test for phenylketonuria and other diseases and conditions

§ 2500-a. Test for phenylketonuria and other diseases and conditions. 1. It shall be the duty of the administrative officer or other person in charge of each institution caring for infants twenty-eight days or less of age and the person required in pursuance of the provisions of section forty-one hundred thirty of this chapter to register the birth of a child, to cause to have administered to every such infant or child in its or his care a test for diseases and conditions designated by the commissioner under regulations of the commissioner, and for:

(a) Phenylketonuria.

(b) Homozygous sickle cell disease.

(c) Hypothyroidism.

(d) Branched-chain ketonuria.

(e) Galactosemia.

(f) Homocystinuria.

(g) Critical congenital heart defects through pulse oximetry screening.

(h) With regard to any newborn infant who is identified as, or suspected of, having a hearing impairment as a result of a screening conducted pursuant to section twenty-five hundred-g of this title, a urine polymerase chain reaction (PCR) test for cytomegalovirus, unless the parent of the infant objects thereto; provided that if the commissioner determines that another test for cytomegalovirus is diagnostically equivalent to or better than the urine polymerase chain reaction test, the commissioner may, by regulation under this section, allow or require the use of that other test.

(i) Adrenoleukodystrophy.

(j) Glucose-6-phosphate dehydrogenase deficiency using a quantitative enzymatic test or other diagnostic test in cases where: the newborn infant presents with hemolytic anemia, hemolytic jaundice, or early-onset increasing neonatal jaundice, that is, jaundice (bilirubin level greater than fortieth percentile for age in hours) persisting beyond the day of birth through the week after birth; the newborn infant has been admitted to the hospital for jaundice following birth; or the biological parent of the newborn infant indicates a family, racial, or ethnic risk of glucose-6-phosphate dehydrogenase deficiency, including having significant African, Asian, Mediterranean, or Middle Eastern ancestry.

(k) Duchenne muscular dystrophy using a test validated by the Wadsworth center for laboratories and research.

2. Testing, the recording of the results of such tests, tracking, follow-up reviews and educational activities shall be performed at such times and in such manner as may be prescribed by the commissioner. The commissioner shall promulgate regulations setting forth the manner in which information describing the purposes of the requirements of this section shall be disseminated to parents or a guardian of the infant tested.

3. The provisions of this section shall not apply in the case of any infant or child whose parent or guardian is a member of a recognized religious organization whose teachings and tenets are contrary to the testing herein required and who notifies the person charged with having such test administered of his objection thereto.